表紙
市場調査レポート

糖尿病性腎障害 : パイプライン分析

Diabetic Nephropathy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192557
出版日 ページ情報 英文 251 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
糖尿病性腎障害 : パイプライン分析 Diabetic Nephropathy - Pipeline Review, H1 2016
出版日: 2016年02月29日 ページ情報: 英文 251 Pages
概要

糖尿病性腎障害とは、糖尿病による発症する腎臓の損傷を指します。疾患の主な特徴としてアルブミン尿や、糸球体濾過率の低下、高血圧などがあります。疾病素質には、肥満症や高血圧、高脂血・高糖血、喫煙などがあります。薬物両用や食生活改善などで症状が緩和する可能性があります。

当レポートでは、世界各国での糖尿病性腎障害治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

糖尿病性腎障害の概要

治療薬の開発

  • 糖尿病性腎障害向けパイプライン製品:概要
  • 糖尿病性腎障害向けパイプライン製品:比較分析

各企業で開発中の糖尿病性腎障害治療薬

大学/研究機関で研究中の糖尿病性腎障害治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

糖尿病性腎障害治療薬:開発中の製品の一覧(企業別)

糖尿病性腎障害治療薬:研究中の製品の一覧(大学/研究機関別)

糖尿病性腎障害治療薬の開発に従事している企業

  • AbbVie Inc.
  • Antisense Therapeutics Limited
  • Arena Pharmaceuticals, Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Cellmid Limited
  • ChemoCentryx, Inc.
  • Concert Pharmaceuticals, Inc.
  • CSL Limited
  • 第一三共
  • Dimerix Bioscience Pty Ltd
  • Dong Wha Pharma Co., Ltd.
  • Dynamis Therapeutics, Inc.
  • Eli Lilly and Company
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • GNI Group Ltd.
  • Islet Sciences, Inc.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • Mallinckrodt Plc
  • Mesoblast Limited
  • 田辺三菱製薬
  • MorphoSys AG
  • NephroGenex, Inc.
  • Noxxon Pharma AG
  • Omeros Corporation
  • 大塚ホールディングス
  • Pfizer Inc.
  • PhytoHealth Corporation
  • ProMetic Life Sciences Inc.
  • Serodus ASA
  • Shire Plc
  • 武田薬品工業
  • Theravance Biopharma, Inc.
  • Tobira Therapeutics, Inc.
  • Vascular Pharmaceuticals, Inc.
  • Vicore Pharma AB
  • XOMA Corporation

糖尿病性腎障害:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 11-RVIVIT
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • A-717
  • 癌用ヘパラナーゼ阻害小分子
  • APD-371
  • APX-115
  • ASP-8232
  • ATL-1103
  • 塩酸アトラセンタン
  • バリシチニブ
  • BI-703704
  • 糖尿病性腎障害向け生物製剤
  • BOT-191
  • C-21
  • カナグリフロジン
  • CCX-140 1
  • cenicriviroc mesylate
  • コルチコトロピン
  • CS-3150
  • CSL-346
  • CTP-499
  • Cyndacel-M
  • DMX-250
  • 糖尿病性心筋症・代謝性疾患向け Nrf2 活性化薬
  • DT-23552
  • DW-1029M
  • DYN-12
  • emapticap pegol
  • finerenone
  • gevokizumab
  • GKT-136901
  • GKT-831
  • GRMD-02
  • GW-610742
  • JD-5037
  • JNJ-39933673
  • リウマチ性関節炎・糖尿病合併症向け MASP-2阻害モノクローナル抗体
  • 癌・炎症性疾患・腎臓病向けミッドカイン阻害モノクローナル抗体
  • MOR-107
  • MPC-300IV
  • MT-3995
  • Nephrilin
  • oxypurinol
  • PBI-4050
  • PBI-4547
  • PF-00489791
  • PHN-033
  • pirfenidone
  • probucol
  • ピリドキサミン二塩化水素化物
  • selonsertib
  • SER-150
  • SHP-627
  • 糖尿病性腎障害向けNOX-4阻害用小分子
  • 糖尿病性腎障害向け小分子
  • 眼科学・心血管・中枢神経系・代謝性疾患向け小分子
  • 転移性癌・糖尿病性腎障害向けヘパラナーゼ阻害小分子
  • SP-20202
  • TAK-272
  • TAK-648
  • TBE-31
  • TD-0714
  • VPI-2690B
  • VS-105
  • XRX-108
  • XRX-221

糖尿病性腎障害治療薬:パイプライン製品の最新動向

糖尿病性腎障害治療薬:開発が休止状態の製品

糖尿病性腎障害治療薬:開発が中止された製品

糖尿病性腎障害関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7648IDB

Summary

Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H1 2016', provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
  • The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Nephropathy Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Nephropathy - Overview
    • Pipeline Products for Diabetic Nephropathy - Comparative Analysis
  • Diabetic Nephropathy - Therapeutics under Development by Companies
  • Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Nephropathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Diabetic Nephropathy - Products under Development by Companies
  • Diabetic Nephropathy - Products under Investigation by Universities/Institutes
  • Diabetic Nephropathy - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Antisense Therapeutics Limited
    • Arena Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bayer AG
    • BiOrion Technologies B.V.
    • Boehringer Ingelheim GmbH
    • Cellmid Limited
    • ChemoCentryx, Inc.
    • Concert Pharmaceuticals, Inc.
    • CSL Limited
    • Daiichi Sankyo Company, Limited
    • Dimerix Bioscience Pty Ltd
    • Dong Wha Pharma Co., Ltd.
    • Dynamis Therapeutics, Inc.
    • Eli Lilly and Company
    • Galectin Therapeutics, Inc.
    • GenKyoTex S.A.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Glucox Biotech AB
    • GNI Group Ltd.
    • Islet Sciences, Inc.
    • Jenrin Discovery, Inc.
    • Johnson & Johnson
    • Mallinckrodt Plc
    • Mesoblast Limited
    • Mitsubishi Tanabe Pharma Corporation
    • MorphoSys AG
    • NephroGenex, Inc.
    • Noxxon Pharma AG
    • Omeros Corporation
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • PhytoHealth Corporation
    • ProMetic Life Sciences Inc.
    • Serodus ASA
    • Shire Plc
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma, Inc.
    • Tobira Therapeutics, Inc.
    • Vascular Pharmaceuticals, Inc.
    • Vicore Pharma AB
    • XOMA Corporation
  • Diabetic Nephropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 11-RVIVIT - Drug Profile
    • A-717 - Drug Profile
    • Antibodies to Inhibit Heparanase for Cancer - Drug Profile
    • APD-371 - Drug Profile
    • APX-115 - Drug Profile
    • ASP-8232 - Drug Profile
    • ATL-1103 - Drug Profile
    • atrasentan hydrochloride - Drug Profile
    • baricitinib - Drug Profile
    • BI-703704 - Drug Profile
    • Biologic for Diabetic Nephropathy - Drug Profile
    • BOT-191 - Drug Profile
    • C-21 - Drug Profile
    • canagliflozin - Drug Profile
    • CCX-140 - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • corticotropin - Drug Profile
    • CS-3150 - Drug Profile
    • CSL-346 - Drug Profile
    • CTP-499 - Drug Profile
    • Cyndacel-M - Drug Profile
    • DMX-250 - Drug Profile
    • Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile
    • DT-23552 - Drug Profile
    • DW-1029M - Drug Profile
    • DYN-12 - Drug Profile
    • emapticap pegol - Drug Profile
    • finerenone - Drug Profile
    • gevokizumab - Drug Profile
    • GKT-136901 - Drug Profile
    • GKT-831 - Drug Profile
    • GRMD-02 - Drug Profile
    • GW-610742 - Drug Profile
    • JD-5037 - Drug Profile
    • JNJ-39933673 - Drug Profile
    • Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile
    • Monoclonal Antibody to Inhibit Midkine for Cancer, Metabolic Disorders and Kidney Diseases - Drug Profile
    • MOR-107 - Drug Profile
    • MPC-300IV - Drug Profile
    • MT-3995 - Drug Profile
    • Nephrilin - Drug Profile
    • oxypurinol - Drug Profile
    • PBI-4050 - Drug Profile
    • PBI-4547 - Drug Profile
    • PF-00489791 - Drug Profile
    • PHN-033 - Drug Profile
    • pirfenidone - Drug Profile
    • probucol - Drug Profile
    • Pyridoxamine Dihydrochloride - Drug Profile
    • selonsertib - Drug Profile
    • SER-150 - Drug Profile
    • SHP-627 - Drug Profile
    • Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile
    • Small Molecules for Diabetic Nephropathy - Drug Profile
    • Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile
    • SP-20202 - Drug Profile
    • TAK-272 - Drug Profile
    • TAK-648 - Drug Profile
    • TBE-31 - Drug Profile
    • TD-0714 - Drug Profile
    • VPI-2690B - Drug Profile
    • VS-105 - Drug Profile
    • XRX-108 - Drug Profile
    • XRX-221 - Drug Profile
  • Diabetic Nephropathy - Recent Pipeline Updates
  • Diabetic Nephropathy - Dormant Projects
  • Diabetic Nephropathy - Discontinued Products
  • Diabetic Nephropathy - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Nephropathy, H1 2016
  • Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Diabetic Nephropathy - Pipeline by AbbVie Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H1 2016
  • Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H1 2016
  • Diabetic Nephropathy - Pipeline by Bayer AG, H1 2016
  • Diabetic Nephropathy - Pipeline by BiOrion Technologies B.V., H1 2016
  • Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Diabetic Nephropathy - Pipeline by Cellmid Limited, H1 2016
  • Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Concert Pharmaceuticals, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by CSL Limited, H1 2016
  • Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2016
  • Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H1 2016
  • Diabetic Nephropathy - Pipeline by Dynamis Therapeutics, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H1 2016
  • Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H1 2016
  • Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H1 2016
  • Diabetic Nephropathy - Pipeline by GNI Group Ltd., H1 2016
  • Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2016
  • Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H1 2016
  • Diabetic Nephropathy - Pipeline by Mesoblast Limited, H1 2016
  • Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Diabetic Nephropathy - Pipeline by MorphoSys AG, H1 2016
  • Diabetic Nephropathy - Pipeline by NephroGenex, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2016
  • Diabetic Nephropathy - Pipeline by Omeros Corporation, H1 2016
  • Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Diabetic Nephropathy - Pipeline by Pfizer Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H1 2016
  • Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2016
  • Diabetic Nephropathy - Pipeline by Shire Plc, H1 2016
  • Diabetic Nephropathy - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Diabetic Nephropathy - Pipeline by Theravance Biopharma, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Tobira Therapeutics, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H1 2016
  • Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2016
  • Diabetic Nephropathy - Pipeline by XOMA Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Diabetic Nephropathy Therapeutics - Recent Pipeline Updates, H1 2016
  • Diabetic Nephropathy - Dormant Projects, H1 2016
  • Diabetic Nephropathy - Dormant Projects (Contd..1), H1 2016
  • Diabetic Nephropathy - Dormant Projects (Contd..2), H1 2016
  • Diabetic Nephropathy - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Diabetic Nephropathy, H1 2016
  • Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top